ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

NCCN in Transition: New Strategy to Examine Role of Informatics, Revenue Sources and International Programs

June 15, 2012

Toxic Substance Act Would Affect Cancer Program

March 21, 1975

In Brief: Obey Was Right- Tests On 70 Chemical Would Have Been Aborted Under NCI Budget

July 20, 1979

Studies Link Age-Dependent Outcome To Immune Cells

November 28, 2003

William Tipping New ACS Executive VP; Murphy To Replace Holleb, Laszio Takes Rauscher’s Position

March 4, 1988

Daily Humidification Improves Quality-of-Life in Phase III Trial

February 28, 2014